EMA Recommends Extension of Indications for Talazoparib
New indications concerns a combination with enzalutamide for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1538 results
A Combination of Trastuzumab with Gemcitabine and Cisplatin Shows Promising Activity in Patients with Treatment-Naïve HER2-positive Biliary Tract Cancer
Findings from the TAB study
FDA Approves Capivasertib with Fulvestrant for Breast Cancer
Evidence for efficacy is evaluated in CAPItello-291 study
PET Positivity After Two Cycles of ABVD Is Associated with a Worse Outcome in Localised Hodgkin Lymphoma Although Intensification with BEACOPPesc Is Safe
Final results of a preplanned analysis at a 10-year follow-up of H10 study
Efficacy Outcomes of Olaparib in Patients with mCRPC with BRCA Alterations Whose Disease Had Progressed on Next-Generation Hormonal Agent
Findings from an exploratory post hoc analysis of the subgroup of patients with BRCA alterations in PROfound study
FDA Approves Fruquintinib for Patients with Refractory Metastatic Colorectal Cancer
Evidence for efficacy is based on the results from the FRESCO-2 and FRESCO studies
EMA Recommends Granting a Conditional Marketing Authorisation for Adagrasib Following a Re-Examination Procedure
It is intended for the treatment of adults with advanced NSCLC with KRAS G12C mutation and disease progression after at least one prior systemic therapy
Adjuvant Atezolizumab Plus Bevacizumab Improves RFS Among Patients at High Risk of HCC Recurrence Following Curative-Intent Resection or Ablation
Findings from the IMbrave050 study
Severe Immune-Related Gastroenterocolitis Described After in Utero Exposure to Pembrolizumab
A new method developed to measure the antibody levels against PD-1
Adding Durvalumab to First-Line Platinum-Based Chemotherapy Followed by Maintenance Durvalumab With Or Without Olaparib Improves PFS for Patients with Advanced Or Recurrent Endometrial Cancer
Findings from the DUO-E study
FDA Approves Toripalimab-tpzi for Nasopharyngeal Carcinoma
Evidence for efficacy is based on the results from the JUPITER-02 and POLARIS-02 studies
Regional Node Radiotherapy Significantly Reduced Breast Cancer Mortality and All-Cause Mortality in Newer but Not in Older Studies
Findings from an individual patient data meta-analysis performed by the Early Breast Cancer Trialists’ Collaborative Group could reflect radiotherapy improvements